Skip to main content

Table 2 Risk factors for the development of diabetes at 12 months

From: Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies

 

Odds ratio (95% CI)

p value

Model 1

 Age, years

1.06 (0.93–1.24)

0.36

 Female sex

0.73 (0.24–2.01)

0.55

 Serum creatinine, mg/dL

0.83 (0.66–0.99)

0.040

 Initial PSL dose, mg/kg/day

3.32 (0.29–41.66)

0.34

 Concomitant cyclophosphamide use

0.29 (0.09–0.87)

0.027

Model 2

 Age, years

1.08 (0.94–1.26)

0.28

 Female sex

0.76 (0.25–2.09)

0.60

 Serum creatinine, mg/dL

0.86 (0.70–1.02)

0.09

 Initial PSL dose, mg/kg/day

1.26 (0.13–14.65)

0.85

 PSL dose at 12 months, mg/day

1.14 (1.00–1.35)

0.045

  1. CI confidential interval, PSL prednisolone